GC Famliy Site

cookie-layer close

COOKIE Setting

When you visit our website, information is stored in your browser or exported in the form of cookies.This information may be about you, your preferences, or the device you use, and is most often used to ensure that the website works properly. This information does not identify you directly, but it can offer a more optimized experience as you navigate our website. Because we respect your right to privacy, you may choose not to allow certain types of cookies. You can check the detailed settings and change them according to your needs.
Analytical cookies

These cookies collect information about how visitors use the website to help improve the site. For example, we anonymously collect information such as the visitor’s device, access area, and time of visit.

  • - Google Analytics (GA4)

    Lorem ipsum dolor sit amet consectetur adipisicing elitsumenda quia nesciunt quo aut soluta. Ipsa qui dolore minima odio facere?

img

Our Affiliate

About Us Our Affiliate
img
img img

Artiva Biotherapeutics develops and brings NK cell therapy products developed at GC Cell to the global market

Website
img

Dedicated to revolutionizing cancer and autoimmune treatment, Artiva’s mission is to deliver cutting-edge, off-the-shelf, allogeneic NK cell-based therapies to patients. Leveraging its strategic partnership with GC Cell, Artiva develops therapies based on Manufacturing-First approach that are not only highly effective but also safe and accessible to cancer patients. At the forefront of Artiva's pipeline is AB-101, an ADCC enhancer NK-cell therapy designed for synergistic use with monoclonal antibodies or innate-cell engagers.

Beyond this, Artiva envisions advancing the field further by developing and commercializing CAR-NK technology developed at GC Cell. With a commitment to advancing the frontiers of biotechnology, Artiva Biotherapeutics and GC Cell stands poised to redefine the landscape of cancer therapeutics, offering hope and innovation to patients worldwide.

Established in 2019
Headquarter San Diego, CA United States
img img

BioCentriq is a global cell therapy Contract Development and Manufacturing Organization(CDMO) with a proven track record successfully transferring, developing, and manufacturing GMP drug product for use in clinical trials.

Website
img

The Executive, Technical, and Business Development teams have commercialized four unique cell therapies and translated more than 20 programs into the clinic. This expertise, coupled with phase-appropriate quality systems and a modern infrastructure have established BioCentriq as a trusted strategic partner for the development and manufacture of autologous and allogeneic cell therapies.

BioCentriq’s four flexible GMP manufacturing suites are supported by fully equipped process and analytical development laboratories to ensure seamless translation from the lab to the clinic.

Established in 2019
Headquarter Newark, NJ United States
img img

GC Lymphotec is dedicated to preventing cancer recurrence through the Sekine method of activated autologous lymphocyte therapy.

Website
img

GC Lymphotec prioritizes improving the health and quality of life for cancer patients and aims to develop life sciences, particularly in regenerative and personalized medicine. Committed to ethical practices, GC Lymphotec strives to ensure its culture technology contributes to healthcare.

The focus includes operating cell therapy products, supplying culture media, collaborating with local medical institutions for cell therapy production, and holding global intellectual property rights and regenerative medicine-related licenses in Japan.
GC Lymphotec stands at the forefront of innovative medical solutions, aiming to make a meaningful impact on individual lives and society.

Established in 1999
Headquarter Tokyo, Japan
img img

GCCL, a company specializing in clinical trial sample analysis and provides analytical services for all phases of clinical trials from phase I to phase IV.

Website
img

GCCL has a platform tailored for clinical trials based on the worldwide quality standards of GCLP accreditation, and provides clinical trial sample analysis services to meet customer needs based on its own sample transportation logistics system as well as various analysis experiences.

GCCL aims to achieve the grand goal of growing into a trusted company that supports the success of clinical trials for partners in the Asian region and around the world as well as in Korea.

Established in 2019
Headquarter Yong-in, Korea